Physician profile
Dirk Davidson
NPI 1659369429
$21,277.07
in general payments reported to CMS, 2019-2025
79 companies · $3,829 in 2025
The $3,829 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,303 · 2020: $2,114 · 2021: $2,923 · 2022: $3,068 · 2023: $3,513 · 2024: $3,528 · 2025: $3,829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,323.08 |
| Education | $547.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,607.08 | 2019-2025 | Calquence, Tagrisso, Enhertu |
| Novartis Pharmaceuticals Corporation | $1,482.90 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,397.83 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Merck Sharp & Dohme LLC | $1,234.69 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $1,162.17 | 2019-2025 | Darzalex, Tecvayli, Erleada |
| Pfizer INC. | $1,126.34 | 2019-2025 | |
| Genentech USA, INC. | $820.32 | 2019-2025 | Tecentriq, Polivy, Venclexta |
| Incyte Corporation | $796.83 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Daiichi Sankyo INC. | $671.77 | 2019-2025 | Enhertu, Injectafer |
| Seagen INC. | $648.80 | 2019-2025 | Tukysa, Padcev, Adcetris |
| Celgene Corporation | $597.69 | 2019-2025 | Reblozyl, Pomalyst, Breyanzi |
| Takeda Pharmaceuticals U.S.A., INC. | $567.35 | 2019-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Bayer Healthcare Pharmaceuticals INC. | $566.39 | 2019-2025 | |
| Astellas Pharma US INC | $517.18 | 2019-2025 | Padcev, Xospata, Vyloy |
| Amgen INC. | $516.59 | 2019-2023 | Kyprolis, Xgeva, Nplate |
Show all 79 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $452.98 | 2019-2023 | Imbruvica |
| Lilly USA, LLC | $449.94 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Gilead Sciences, INC. | $431.46 | 2019-2025 | Trodelvy |
| Aveo Pharmaceuticals, INC. | $360.10 | 2022-2025 | Fotivda |
| Regeneron Healthcare Solutions, INC. | $347.71 | 2019-2025 | Libtayo |
| Abbvie INC. | $332.50 | 2020-2025 | Venclexta |
| Glaxosmithkline, LLC. | $301.04 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Array Biopharma INC | $279.52 | 2020-2025 | Braftovi, Mektovi, Lorbrena |
| Eisai INC. | $276.62 | 2019-2025 | |
| Genzyme Corporation | $271.49 | 2019-2025 | |
| Emd Serono, INC. | $259.80 | 2019-2025 | Bavencio |
| Exelixis INC. | $241.12 | 2019-2025 | Cabometyx |
| Deciphera Pharmaceuticals INC. | $218.64 | 2021-2025 | Qinlock, Romvimza |
| Pharmacosmos Therapeutics INC. | $191.96 | 2020-2025 | Monoferric |
| Mirati Therapeutics, INC. | $185.19 | 2023-2024 | Krazati |
| Ipsen Biopharmaceuticals, INC | $177.22 | 2019-2024 | Onivyde |
| Beigene USA, INC. | $149.83 | 2020-2025 | Brukinsa |
| Coherus Oncology, INC. | $132.35 | 2021-2024 | |
| Morphosys, US INC. | $132.33 | 2022-2023 | Monjuvi |
| Eusa Pharma (US) LLC | $129.81 | 2019-2022 | |
| Rigel Pharmaceuticals, INC. | $120.56 | 2022-2025 | Rezlidhia, Tavalisse, Gavreto |
| Puma Biotechnology, INC. | $119.81 | 2020-2024 | |
| Alexion Pharmaceuticals, INC. | $112.78 | 2019-2023 | Ultomiris |
| Sobi, INC | $111.18 | 2022-2023 | |
| Pharmaessentia USA Corporation | $103.44 | 2022-2025 | Besremi |
| Tersera Therapeutics LLC | $99.96 | 2022-2025 | Quzyttir, Zoladex |
| Karyopharm Therapeutics INC. | $97.88 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.60 | 2019-2025 | Gilotrif |
| Adaptive Biotechnologies Corporation | $91.27 | 2022-2024 | Clonoseq |
| Dova Pharmaceuticals | $88.54 | 2019-2021 | |
| Kite Pharma, INC. | $84.35 | 2020-2023 | Yescarta |
| Genmab U.S., INC. | $74.72 | 2023-2025 | Epkinly |
| Jazz Pharmaceuticals INC. | $74.64 | 2021-2024 | Zepzelca |
| Caris Mpi, INC. | $70.49 | 2025 | Mi Cancer Seek |
| Sun Pharmaceutical Industries INC. | $70.35 | 2020-2024 | |
| Acceleron Pharma, INC. | $69.55 | 2020-2021 | |
| Taiho Oncology, INC. | $57.21 | 2019-2025 | |
| Beone Medicines USA, INC. | $57.03 | 2025 | Brukinsa, Tevimbra |
| Verity Pharmaceuticals INC. | $47.63 | 2023-2024 | Trelstar |
| Secura Bio, INC. | $41.33 | 2019-2024 | Copiktra |
| Otsuka America Pharmaceutical, INC. | $40.59 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $37.19 | 2019-2024 | Akynzeo |
| Sandoz INC. | $37.18 | 2025 | Jubbonti, Wyost |
| Azurity Pharmaceuticals, INC. | $34.92 | 2024-2025 | Vivimusta, Danziten |
| Stemline Therapeutics INC. | $32.93 | 2023 | Orserdu |
| Teva Pharmaceuticals USA, INC. | $30.41 | 2019 | |
| Avyxa Pharma, LLC | $26.83 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $24.47 | 2019-2020 | |
| Tolmar, INC. | $22.82 | 2025 | Rubraca, Eligard |
| Pharmaand Gmbh | $22.82 | 2025 | Rubraca |
| Tg Therapeutics, INC. | $22.37 | 2021 | |
| Clovis Oncology, INC. | $21.93 | 2021 | |
| Organon LLC | $20.52 | 2022 | |
| Acrotech Biopharma INC. | $19.95 | 2025 | Ryzneuta |
| Agios Pharmaceuticals, INC. | $19.81 | 2025 | Pyrukynd |
| Spectrum Pharmaceuticals INC. | $19.05 | 2025 | Rolvedon |
| Accord Healthcare, INC. | $17.81 | 2024 | |
| Fennec Pharmaceuticals, INC. | $16.92 | 2024 | Pedmark |
| Progenics Pharmaceuticals, INC. | $15.02 | 2023 | Pylarify |
| Foundation Medicine, INC. | $14.80 | 2022 | |
| Macrogenics, INC. | $14.11 | 2022 | |
| Verastem, INC. | $13.77 | 2019 | |
| Tesaro, INC. | $13.24 | 2019 | |
| Kyowa Kirin, INC. | $12.75 | 2023 | Poteligeo |
Drugs and devices associated with these payments
Keytruda $558Enhertu $524Opdivo $355Reblozyl $351Fotivda $335Imbruvica $324Kisqali $318Jaypirca $296Verzenio $276Jakafi $259Tukysa $255Xtandi $248Ibrance $247Libtayo $231Padcev $225Retevmo $218Krazati $218Monjuvi $213Darzalex $212Talzenna $205Orgovyx $198Tecvayli $186Nubeqa $184Venclexta $183Trodelvy $178Scemblix $177Adcetris $166Lenvima $165Elrexfio $158Xofigo $154Brukinsa $145Calquence $139Lynparza $137Ojjaara $134Erleada $134Tagrisso $130Braftovi $125Opdualag $124Epkinly $116Lorbrena $112Qinlock $108Mektovi $107Lutathera $105Pomalyst $101Tecentriq $98.89Welireg $92.00Pemazyre $91.20Akeega $90.86Rybrevant $90.31Polivy $89.66Sarclisa $88.78Stivarga $86.12Cabometyx $85.79Inlyta $84.78Rezlidhia $81.32Tavalisse $81.32Besremi $79.86Bosulif $77.56Monoferric $75.24Zynyz $71.53Mi Cancer Seek $70.49Vitrakvi $68.07Balversa $62.85Ninlaro $62.64Mekinist $61.77Perjeta $60.74Phesgo $60.74Paxlovid $60.53Romvimza $59.32Clonoseq $58.03Alunbrig $56.10Xalkori $51.50Comirnaty $51.41Zepzelca $51.19Elahere $50.39Imfinzi $49.59Fruzaqla $48.37Iclusig $48.11Injectafer $47.87Trelstar $47.63Itovebi $47.37Rubraca $45.64Xospata $45.41Vyloy $40.50Bavencio $38.62Gilotrif $37.96Promacta $37.80Jubbonti $37.18Wyost $37.18Udenyca $36.29Talvey $35.29Vivimusta $34.92Quzyttir $34.40Doptelet $33.77Orserdu $32.93Kyprolis $29.89Onivyde $28.57Ayvakit $28.18Avgemsi $26.83Lutrate Depot $26.83
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dirk Davidson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.